- Tanvex BioPharma has appointed Stephen Lam as Chief Executive Officer, effective September 5, 2024, as part of its ongoing strategic alliance with Bora Pharmaceuticals.
- Lam will oversee Tanvex’s global CDMO operations and biosimilar commercialization, bringing over 35 years of industry experience.
Tanvex BioPharma Inc., a biosimilar-focused biopharmaceutical company and CDMO, has announced the appointment of Stephen Lam as its new Chief Executive Officer, effective September 5, 2024. Lam succeeds Henry Chen, who will remain the company’s Chairman until the completion of its strategic alliance with Bora Pharmaceuticals Co., Ltd.
Lam’s responsibilities will include overseeing Tanvex’s global operations as a contract manufacturing provider, alongside leading the company’s efforts to commercialize its biosimilar pipeline. His appointment follows Bora Pharmaceuticals’ involvement in shaping Tanvex’s leadership, with a focus on successful integration and advancing strategic initiatives.
With more than 35 years of experience in the biopharmaceutical sector, Lam has held key roles at companies such as Lonza, Amgen, Patheon, and most recently, Thermo Fisher Scientific, where he served as Vice President and General Manager, Head of Biologics. His background includes a proven record of driving operational success in biologics manufacturing.
“I am honoured to take on the role of CEO at Tanvex. By integrating Tanvex’s established commercial biologics manufacturing with Bora’s strong reputation, industry-leading quality, and proven process development expertise, we can serve our customers no matter where they are in their drug development lifecycle, from First-In-Human studies through to commercial launch,” said Lam.
Overview of outsourcing trends 
